Icon Bioscience Reports Successful Outcomes Of Phase 3 Study Of Ibi-10090, A Novel Sustained Release Drug Being Developed To Treat Inflammation Associated With Cataract Surgery
Detailed Results to be Presented at 2015 ASCRS-ASOA Symposium & Congress Sunnyvale, CA (April 6, 2015) – Icon Bioscience Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug delivery platform to develop unique intraocular eye-care therapeutics, today announced…